Karen Walker
Directeur Technique/Scientifique/R&D chez KYVERNA THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Profil
Karen Walker is currently the Chief Technology Officer at Kyverna Therapeutics, Inc. She is also a member of the Parenteral Drug Association, Alliance For Regenerative Medicine’s Foundation, and PDA ATMP Working Group.
Previously, she held the position of Vice President at Novartis, Inc. and Seagen Inc. Ms. Walker received her undergraduate degree from St. Olaf College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Karen Walker
| Sociétés | Poste | Début |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2021 |
| Alliance For Regenerative Medicine’S Foundation | Corporate Officer/Principal | - |
| Parenteral Drug Association | Corporate Officer/Principal | - |
Anciens postes connus de Karen Walker
| Sociétés | Poste | Fin |
|---|---|---|
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Corporate Officer/Principal | - |
| SEAGEN INC. | Corporate Officer/Principal | - |
Formation de Karen Walker
| St. Olaf College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
| Parenteral Drug Association | |
| Alliance For Regenerative Medicine’S Foundation |
